Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?-Reference-Cited by-同舟云学术

Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?

Published:2019 Issue:5 Volume:31 Page:495
ISSN:1013-9087
Container-title:Annals of Dermatology
language:en
Short-container-title:Ann Dermatol

Author:

Kim Byungsoo¹²^ORCID,Maverakis Emanual³^ORCID,Raychaudhuri Siba P.⁴⁵^ORCID

Affiliation:

1. Department of Dermatology, Pusan National University School of Medicine, Yangsan, Korea.

2. Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.

3. Department of Dermatology, School of Medicine, University of California Davis, Sacramento, CA, USA.

4. Division of Rheumatology and Immunology, Veterans Affairs Medical Center Sacramento, Sacramento, CA, USA.

5. Division of Rheumatology, Allergy and Clinical Immunology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, CA, USA.

Publisher

Korean Dermatological Association and The Korean Society for Investigative Dermatology

Subject

Dermatology

Link

https://synapse.koreamed.org/pdf/10.5021/ad.2019.31.5.495

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is it possible to optimize biologic therapy in patients with psoriasis?;Revista Colombiana de Reumatología (English Edition);2024-04

2. Is it possible to optimize biologic therapy in patients with psoriasis?;Revista Colombiana de Reumatología;2022-12

3. Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis;Frontiers in Immunology;2022-10-21

4. The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era;Rheumatology International;2022-05-03

5. Comparison of Th1 and Th17 Inflammatory Cytokine Profiles Between Chronic Plaque and Acute Guttate Psoriasis;Annals of Dermatology;2022